Patents by Inventor Zbigniew Pietrzkowski

Zbigniew Pietrzkowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170216331
    Abstract: Contemplated compositions and methods employ betalains for treatment of various conditions, and especially osteoarthritis, sinusitis, contact dermatitis, acne, an allergic condition, reduced mental alertness, reduced physical strength, reduced physical endurance, and/or impaired mood.
    Type: Application
    Filed: April 14, 2017
    Publication date: August 3, 2017
    Inventor: Zbigniew Pietrzkowski
  • Patent number: 9636371
    Abstract: Contemplated compositions and methods employ betalains for treatment of various conditions, and especially osteoarthritis, sinusitis, contact dermatitis, acne, an allergic condition, reduced mental alertness, reduced physical strength, reduced physical endurance, and/or impaired mood.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: May 2, 2017
    Assignee: VDF Futureceuticals, Inc.
    Inventor: Zbigniew Pietrzkowski
  • Patent number: 9327005
    Abstract: Compositions and methods for dietary supplements that contain a cold-water extract of humic shale and/or an extract of the apple fruit or skin of the apple fruit that is/are effective to modulate in vivo cytokines, oxygen consumption rate, extracellular acidification rate, and ATP production.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: May 3, 2016
    Assignee: VDF Futureceuticals, Inc.
    Inventor: Zbigniew Pietrzkowski
  • Patent number: 9271994
    Abstract: Contemplated compositions and methods are drawn to use of various boron-containing compounds to temporarily and transiently increase endogenous blood calcitriol concentration. The boron-containing compound is preferably a carbohydrate-boron complex having sufficient stability to achieve measurable quantities of the complex in blood upon oral administration of the complex.
    Type: Grant
    Filed: August 7, 2014
    Date of Patent: March 1, 2016
    Assignee: VDF Futureceuticals, Inc.
    Inventor: Zbigniew Pietrzkowski
  • Publication number: 20160038557
    Abstract: Compositions and methods are presented that substantially increase levels of BDNF in blood, and even more pronouncedly exosomal BDNF levels. Suitable compositions include whole coffee fruit extracts and powders or procyanidin-enriched preparations that are orally administered at relatively low dosages. The augmentation of the levels of natural stimulating factor takes place in cerebral circulation.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 11, 2016
    Inventor: Zbigniew Pietrzkowski
  • Publication number: 20150322106
    Abstract: Solid, free-flowing, and substantially completely dissolvable preparations with high betalain content are presented. Most typically, the betalain profile of the preparations is near natural and includes betalains in an amount of between 10-40 wt %. As the preparations of the inventive subject matter maintain chemical stability and flowability over extended periods of time, it should be noted that the betalain preparations are now amenable to compounding in small and measured quantities. Furthermore, new biological activities of betalains are shown, and especially include significant induction of SIRT and reduction of serum triglyceride.
    Type: Application
    Filed: July 2, 2015
    Publication date: November 12, 2015
    Inventors: Zbigniew Pietrzkowski, Wayne Carl Thresher
  • Publication number: 20150258154
    Abstract: Contemplated compositions and methods employ betalains for treatment of various conditions, and especially osteoarthritis, sinusitis, contact dermatitis, acne, an allergic condition, reduced mental alertness, reduced physical strength, reduced physical endurance, and/or impaired mood.
    Type: Application
    Filed: May 29, 2015
    Publication date: September 17, 2015
    Inventor: Zbigniew Pietrzkowski
  • Patent number: 9101587
    Abstract: Solid, free-flowing, and substantially completely dissolvable preparations with high betalain content are presented. Most typically, the betalain profile of the preparations is near natural and includes betalains in an amount of between 10-40 wt %. As the preparations of the inventive subject matter maintain chemical stability and flowability over extended periods of time, it should be noted that the betalain preparations are now amenable to compounding in small and measured quantities. Furthermore, new biological activities of betalains are shown, and especially include significant induction of SIRT and reduction of serum triglyceride.
    Type: Grant
    Filed: January 31, 2008
    Date of Patent: August 11, 2015
    Assignee: VDF Futureceuticals, Inc.
    Inventors: Zbigniew Pietrzkowski, Wayne Carl Thresher
  • Patent number: 9060539
    Abstract: Contemplated compositions and methods employ betalains for treatment of various conditions, and especially osteoarthritis, sinusitis, contact dermatitis, acne, an allergic condition, reduced mental alertness, reduced physical strength, reduced physical endurance, and/or impaired mood.
    Type: Grant
    Filed: July 30, 2009
    Date of Patent: June 23, 2015
    Assignee: VDF Futureceuticals, Inc.
    Inventor: Zbigniew Pietrzkowski
  • Publication number: 20140349951
    Abstract: Contemplated compositions and methods are drawn to use of various boron-containing compounds to temporarily and transiently increase endogenous blood calcitriol concentration. The boron-containing compound is preferably a carbohydrate-boron complex having sufficient stability to achieve measurable quantities of the complex in blood upon oral administration of the complex.
    Type: Application
    Filed: August 7, 2014
    Publication date: November 27, 2014
    Inventor: Zbigniew Pietrzkowski
  • Publication number: 20140274919
    Abstract: Contemplated boro-carbohydrate compounds are demonstrated to modulate the blood concentrations of various polypeptides associated with metabolic syndrome by administration of a tetrahedral, and under-carboxylated osteocalcin, adiponectin, and YKL-40. Use of such compounds in oral administration is especially preferred and may be effective to address one or more components of metabolic syndrome.
    Type: Application
    Filed: May 17, 2012
    Publication date: September 18, 2014
    Applicant: VDF FutureCeuticals, Inc.
    Inventor: Zbigniew Pietrzkowski
  • Patent number: 8809284
    Abstract: Contemplated compositions and methods are drawn to use of various boron-containing compounds to temporarily and transiently increase endogenous blood calcitriol concentration. The boron-containing compound is preferably a carbohydrate-boron complex having sufficient stability to achieve measurable quantities of the complex in blood upon oral administration of the complex.
    Type: Grant
    Filed: April 5, 2010
    Date of Patent: August 19, 2014
    Assignee: VDF Futureceuticals, Inc.
    Inventor: Zbigniew Pietrzkowski
  • Patent number: 8642651
    Abstract: Complex metal-containing matrices, and especially chromium-containing matrices are produced from a water soluble preparation that is derived from an item suitable for animal (and most typically human) consumption. In particularly contemplated aspects, the water soluble preparation is an extract or filtrate of disintegrated brewer's yeast, and the so prepared complex mixture is combined with a chromium-3+ ions.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: February 4, 2014
    Assignee: VDF Futureceuticals, Inc.
    Inventors: Dusan Miljkovic, Jovan Hranisavljevic, Zbigniew Pietrzkowski
  • Patent number: 8476017
    Abstract: Methods and compositions for diagnosis and/or analysis of a condition in a mammal are disclosed in which RNA from microvesicles is enriched and differentiated to so obtain a result that is indicative of the condition of tissue or organ from which the microvesicle originated. In especially preferred embodiments, the condition is a neoplastic disease of a human and can be identified and staged by differential analysis of one or more distinct RNAs, optionally together with identification and analysis of a non-RNA component of the microvesicle.
    Type: Grant
    Filed: September 15, 2011
    Date of Patent: July 2, 2013
    Assignee: Proxy Life Sciene Holdings, Inc.
    Inventor: Zbigniew Pietrzkowski
  • Patent number: 8124135
    Abstract: Dicot, and especially Brassicaceae sprout preparations are employed as a dietary agents that significantly reduce oxidized species in human serum. In one especially preferred aspect, contemplated compositions are employed to reduce serum oxLDL and to increase serum HDL levels.
    Type: Grant
    Filed: May 24, 2006
    Date of Patent: February 28, 2012
    Assignee: VDF FutureCeuticals, Inc.
    Inventor: Zbigniew Pietrzkowski
  • Publication number: 20120009578
    Abstract: Methods and compositions for diagnosis and/or analysis of a condition in a mammal are disclosed in which RNA from microvesicles is enriched and differentiated to so obtain a result that is indicative of the condition of tissue or organ from which the microvesicle originated. In especially preferred embodiments, the condition is a neoplastic disease of a human and can be identified and staged by differential analysis of one or more distinct RNAs, optionally together with identification and analysis of a non-RNA component of the microvesicle.
    Type: Application
    Filed: September 15, 2011
    Publication date: January 12, 2012
    Applicant: PROXY LIFE SCIENCE HOLDINGS, INC.
    Inventor: Zbigniew Pietrzkowski
  • Patent number: 8088752
    Abstract: Pharmaceutical compositions include compounds with cytokinin activity to modulate glucose and/or lipid metabolism in a mammal. Especially preferred compounds include those comprising a purine scaffold, and it is further preferred that contemplated compositions are employed to prevent and/or treat various diseases, including pre-diabetes, insulin resistance, type-2 diabetes, Syndrome X, and dyslipidemia. In still further preferred aspects, compounds with cytokinin activity are used to activate AMPK and/or Akt. Consequently, various diseases associated with dysregulation of AMPK and/or Akt may be treated using the compounds of the present inventive subject matter.
    Type: Grant
    Filed: April 7, 2009
    Date of Patent: January 3, 2012
    Assignee: VDF FutureCeuticals, Inc.
    Inventors: Dusan Miljkovic, Jovan Hranisavljevic, Zbigniew Pietrzkowski
  • Publication number: 20110274728
    Abstract: Various compositions and methods are provided to alleviate one or more symptoms associated with hyposalivation or xerostomia. Preferred compositions and methods employ one or more plant extracts and/or a proanthocyanidin at a concentration effective to reduce or eliminate the symptoms. Especially preferred extracts are isolated from a fruit and/or seed (e.g., grape, cranberry, blue berry, black berry, etc.), and where a second extract is present, such extract is preferably isolated from a citrus fruit (e.g., lemon, orange, lime, grapefruit, tangerine, mandarin orange, ugli fruit, etc.).
    Type: Application
    Filed: November 13, 2009
    Publication date: November 10, 2011
    Inventors: David Hamlin, Satyanarayana Majeti, Zbigniew Pietrzkowski
  • Publication number: 20110275078
    Abstract: Contemplated compositions and methods are directed to the use of microvesicles from an optionally recombinant donor cell to impart a desirable effect to a recipient cell. In certain preferred aspects, RNA of the microvesicles is employed to achieve the desirable effect. For example, microvesicles are used in vitro to increase the number of passages of a cell growing in a medium, reduce serum and/or growth factor requirements of a cell growing in a medium, and/or delay differentiation of a cell growing in a medium. Further preferred aspects include use of the microvesicles as therapeutic agents in which RNA, a membrane protein, and/or a cytosolic protein encapsulated in or coupled to the microvesicle provide a therapeutic effect. Additionally, diagnostic methods are contemplated in which RNA of a microvesicle isolated from a mammal is associated with a condition of the mammal.
    Type: Application
    Filed: July 12, 2011
    Publication date: November 10, 2011
    Inventor: Zbigniew Pietrzkowski
  • Publication number: 20110274679
    Abstract: Compositions and methods of SIRT activation are presented in which one or more vitamin compounds, and especially vitamin B compounds are used to significantly increase SIRT activity in vitro and in vivo. In especially preferred compositions, vitamin B6, vitamin B12, and vitamin B2 are present in synergistic quantities.
    Type: Application
    Filed: November 5, 2009
    Publication date: November 10, 2011
    Applicant: VDF FutureCeuticals, Inc.
    Inventor: Zbigniew Pietrzkowski